Login
About Alexion
Our Leadership
Our Partnerships
Our Ethical Standards
Our History
Patient Focus
Advocacy
Patient Stories
Products
Soliris
®
PNH
aHUS
Strensiq
®
Kanuma
®
Research & Development
Our Pipeline
Development Programs
Investigator-Sponsored Research
Discovery Partnerships
Responsibility
Global Access to Medicines Policy
Main Menu
Careers
Job Opportunities
Why Choose Alexion
Culture
Compensation & Benefits
Work/Life Balance
Health & Wellness
Financial Security
Recognition & Rewards
Personal Growth & Development
Professional Development
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Select a Country
Investors
News
Contact
Search for:
North America
Canada
United States
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
United Kingdom
Asia Pacific
Australia
China
India
Japan
About Alexion
Patient Focus
Products
Research & Development
Responsibility
Careers
Select a Country
North America
Canada
USA
Latin America
Argentina
Brazil
Colombia
Mexico
Europe, the Middle East & Africa
Alexion Europe
Belgium
Denmark
France
Germany
Ireland
Italy
Netherlands
Norway
Russia
Spain
Sweden
Switzerland
Turkey
UAE
UK
Asia Pacific
Australia
China
India
Japan
Investors
News
Contact
Home
»
Newsroom
»
Press Releases
»
Product News
Product News
Press Releases
Filter by Category
All Press Releases
Company Releases
Company Statements
Financial Releases
Product Releases
Sort by Year
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
Media
Inquiries
Media
Materials
Email
Alerts
Search Newsroom
Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis
December 10, 2014
HTML
PDF
New Data Presented at ASH Annual Meeting Enhance Clinical Knowledge of aHUS and PNH and Underscore the Effectiveness of Soliris® (eculizumab) Treatment
December 8, 2014
HTML
PDF
NICE Issues Final Positive Recommendation for National Commissioning of Soliris® (eculizumab) for All Patients with aHUS in England
November 27, 2014
HTML
PDF
Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
November 25, 2014
HTML
PDF
Longer-term Outcome Data from the Largest Prospective Trial of Soliris® (eculizumab) in aHUS Underscore the Effectiveness of Ongoing Soliris Treatment
November 15, 2014
HTML
PDF
Researchers to Present Data on Improving the Understanding of PNH and aHUS and Underscoring the Effectiveness of Soliris® (eculizumab) Treatment at ASH 2014 Annual Meeting
November 6, 2014
HTML
PDF
Researchers to Present Data on Soliris® (eculizumab) as a Treatment for Patients with aHUS at ASN 2014 Annual Meeting
October 23, 2014
HTML
PDF
Alexion Submits NDA in Japan for Asfotase Alfa as a Treatment for Patients with Hypophosphatasia
October 15, 2014
HTML
PDF
Improved Survival Observed in Pediatric Patients with Severe Hypophosphatasia (HPP) Who Were Treated with Investigational Asfotase Alfa for Up to Five Years
September 14, 2014
HTML
PDF
Asfotase Alfa Granted Orphan Drug Designation in Japan
September 8, 2014
HTML
PDF
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »
